Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4088957 | 0.94 | P2RY12 (0.88) | P2RY12 | |
| SCHEMBL3924543 | 0.93 | P2RY12 (1.00) | P2RY12 | |
| SCHEMBL3935941 | 0.93 | P2RY12 (1.00) | P2RY12 | |
| SCHEMBL3925458 | 0.92 | P2RY12 (1.00) | P2RY12 | |
| SCHEMBL4095121 | 0.92 | P2RY12 (1.00) | P2RY12 | |
| SCHEMBL3923748 | 0.92 | P2RY12 (0.87) | P2RY12ALDH1A1 | |
| SCHEMBL3921936 | 0.92 | P2RY12 (1.00) | P2RY12 | |
| SCHEMBL3931864 | 0.92 | P2RY12 (0.88) | P2RY12 | |
| SCHEMBL4095843 | 0.91 | P2RY12 (1.00) | P2RY12 | |
| SCHEMBL3926550 | 0.91 | P2RY12 (0.85) | P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186876-A1 | Pyridine Analogues II | ASTRAZENECA AB (SE) | 2009-07-23 | — | — | US | claimed |
| EP-2041111-A1 | NEW PYRIDINE ANALOGUES | AstraZeneca AB (SE) | 2009-04-01 | — | — | EP | claimed |
| WO-2008002247-A1 | NEW PYRIDINE ANALOGUES | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | claimed |
| US-20070244088-A1 | New Pyridine Analogues II | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | claimed |
| US-20090186876-A1 | Pyridine Analogues II | ASTRAZENECA AB (SE) | 2009-07-23 | — | — | US | disclosed |
| EP-2041111-A1 | NEW PYRIDINE ANALOGUES | AstraZeneca AB (SE) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008002247-A1 | NEW PYRIDINE ANALOGUES | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20070244088-A1 | New Pyridine Analogues II | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244088-A1 | New Pyridine Analogues II | P2RY12, P2RY1, P2RY11 | P2RY12 1/4885ALDH1A1 2018/4885 |
| US-20090186876-A1 | Pyridine Analogues II | P2RY12, P2RY11, P2RY6 | P2RY12 1/4885ALDH1A1 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.